A Phase III Double-Blind Randomisation Study Accessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPltello-290)

Status

Closed

Disease

Triple Negative Breast Cancer

Treament Agent

Capivasertib + Paclitaxel vs Placebo + Paclitaxel

Study Phase

III

Resources and Links

clinicaltrials.gov NCT03997123

Physician Name(s)

Dr Mastura Md Yusof

Dr John Low Seng Hooi

Description

Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPltello-290)

Cancer Type

Breast Cancer

I would like to be a part of tomorrow's breakthrough

Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.

In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.

If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: